Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Myeloma

Clinical outcomes with intensive therapy for patients with primary resistant multiple myeloma

Bone Marrow Transplantation volume 34, pages 229–234 (2004)Cite this article

Summary:

Clinical outcomes were evaluated in 89 consecutive patients with multiple myeloma that had not responded to dexamethasone-based primary therapy, who received early intensive therapy supported by autologous stem cell transplantation. Results were compared with those of 45 comparable patients who refused or were unable to receive intensive treatment for socioeconomic reasons. Following high-dose therapy, the response rate was 69% including 16% with CR. Survival of 14 patients with CR (median >7.0 years) was significantly longer than those of 47 patients with PR (median 4.5 years) or of 28 patients who remained NR (median 2.2 years). CR occurred in 43% of patients with serum myeloma protein <1.5 gm/dl, in contrast to 7% of those with higher values, a finding similar to that observed previously for patients consolidated in PR. No prognostic factor was associated with PR and, in view of the high frequencies of PR or CR, all patients with primary resistant myeloma should be considered for early intensive therapy. The limited improvement of lifespan and disease-free survival for those in PR indicated the need for further treatment to achieve CR, the major surrogate marker for long survival.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Barlogie B, Alexanian R, Dicke K et al. High dose chemoradiotherapy and autologous bone marrow transplantation for resistant multiple myeloma. Blood 1987; 70: 868–872.

    Google Scholar 

  2. Cunningham D, Pazares L, Gore M et al. High-dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated multiple myeloma. J Clin Oncol 1994; 12: 759–763.

    Article  CAS  PubMed  Google Scholar 

  3. Alexanian R, Dimopoulos M, Hester J et al. Early myeloablative therapy for multiple myeloma. Blood 1994; 84: 4278–4282.

    CAS  PubMed  Google Scholar 

  4. Attal M, Harosseau J, Stoppa J et al. Autologous bone marrow transplantation versus conventional chemotherapy in multiple myeloma. N Engl J Med 1996; 335: 91–97.

    Article  CAS  PubMed  Google Scholar 

  5. Bensinger W, Rowley S, Demirer T et al. High-dose therapy followed by autologous hematopoietic stem-cell infusion for patients with multiple myeloma. J Clin Oncol 1996; 14: 1447–1456.

    Article  CAS  PubMed  Google Scholar 

  6. Barlogie B, Jagannath S, Vesole D et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 1997; 89: 789–793.

    CAS  PubMed  Google Scholar 

  7. Child J, Morgan G, Davies F et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875–1883.

    Article  CAS  PubMed  Google Scholar 

  8. Tricot G, Barlogie B, Jagannath S et al. Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosomes 13 and not with other karyotype abnormalities. Blood 1995; 86: 4250–4256.

    CAS  PubMed  Google Scholar 

  9. Blade J, San Miguel J, Fontanillas M et al. Survival of multiple myeloma patients who are potential candidates for early high-dose therapy intensification/autotransplantation who were conventionally treated. J Clin Oncol 1996; 14: 2167–2173.

    Article  CAS  PubMed  Google Scholar 

  10. Lahuerta J, Martinez-Lopez J, de la Serna J et al. Remission status defined by immunofixation vs electrophoresis after autologous transplantation has a major impact on the outcome of multiple myeloma patients. Br J Haematol 2000; 109: 438–446.

    Article  CAS  PubMed  Google Scholar 

  11. Alexanian R, Weber D, Giralt S et al. Impact of complete remission with intensive therapy in patients with responsive multiple myeloma. Bone Marrow Transplant 2001; 27: 1037–1043.

    Article  CAS  PubMed  Google Scholar 

  12. Alexanian R, Barlogie B, Tucker S . VAD-based regimens as primary treatment for multiple myeloma. Am J Hematol 1990; 33: 86–89.

    Article  CAS  PubMed  Google Scholar 

  13. Alexanian R, Dimopoulos M, Delasalle K, Barlogie B . Primary dexamethasone treatment of multiple myeloma. Blood 1992; 80: 887–890.

    CAS  PubMed  Google Scholar 

  14. Weber D, Dimopoulos M, Gavino M et al. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 2003; 21: 16–19.

    Article  CAS  PubMed  Google Scholar 

  15. Dimopoulos M, Alexanian R, Przepiorka et al. A new preparative regimen for autologous marrow or blood stem cell transplantation in high-risk multiple myeloma. Blood 1993; 82: 2324–2328.

    CAS  PubMed  Google Scholar 

  16. Giralt S, Bensinger W, Goodman M et al. 166Ho-DOTMP plus melphalan followed by peripheral blood stem cell transplantation in patients with multiple myeloma. Blood 2003; 102: 2684–2691.

    Article  CAS  PubMed  Google Scholar 

  17. McLaughlin P, Alexanian R . Myeloma protein kinetics following chemotherapy. Blood 1982; 60: 851–955.

    CAS  PubMed  Google Scholar 

  18. Vose J, Anderson J, Kessinger A et al. High-dose chemotherapy and autologous hematopoetic stem-cell transplantation for aggressive non-Hodgkin's lymphoma. J Clin Oncol 1993; 11: 1846–1851.

    Article  CAS  PubMed  Google Scholar 

  19. Rajkumar S, Fonseca R, Lacy M et al. Autologous stem cell transplantation for relapsed and primary refractory myeloma. Bone Marrow Transplant 1999; 23: 1267–1272.

    Article  CAS  PubMed  Google Scholar 

  20. Vesole D, Crowley J, Catchatourian R et al. High-dose melphalan with autotransplantation for refractory multiple myeloma: results of a Southwest Oncology Group phase II trial. J Clin Oncol 1999; 17: 2173–2179.

    Article  CAS  PubMed  Google Scholar 

  21. Singhal S, Powles R, Sirohi B et al. Response to induction chemotherapy is not essential to obtain survival benefit from high-dose melphalan and autotransplantation in myeloma. Bone Marrow Transplant 2002; 30: 673–679.

    Article  CAS  PubMed  Google Scholar 

  22. Bensinger W, Maloney D, Sandmaier B et al. Non-myeloablative allogeneic transplant strategies for the treatment of multiple myeloma. Hematol J 2003; 4 (Suppl. 1): S68 (abstract).

    Google Scholar 

  23. Richardson P, Barlogie B, Berenson J et al. A phase 2 study of bortezomid in relapsed refractory myeloma. N Engl J Med 2003; 348: 2609–2617.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank Rose Guevara for careful preparation of the manuscript. This work was supported by Lucille Murchison and Kay Laro research funds.

Author information

Authors and Affiliations

  1. University of Texas MD Anderson Cancer Center, Houston, TX, USA

    R Alexanian, D Weber, K Delasalle, B Handy, R Champlin & S Giralt

Authors
  1. R Alexanian
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D Weber
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. K Delasalle
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. B Handy
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. R Champlin
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. S Giralt
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R Alexanian.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Alexanian, R., Weber, D., Delasalle, K. et al. Clinical outcomes with intensive therapy for patients with primary resistant multiple myeloma. Bone Marrow Transplant 34, 229–234 (2004). https://doi.org/10.1038/sj.bmt.1704562

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1704562

Keywords

This article is cited by

Search

Advanced search

Quick links